Drug Combination Details
| General Information of the Combination (ID: C03422) | |||||
|---|---|---|---|---|---|
| Name | Vanillic acid NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Healthy individual
[ICD-11: N.A.]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | TLR4 | Molecule Info |
Pathway MAP
|
|
| In-vivo Model | Male Wistar albino rats weighing 200 +/- 20 g were used in this study. | |||||
| Experimental
Result(s) |
VA exerts cardioprotective effects against DOX-induced cardiotoxicity by decreasing oxidative stress and biomarkers of cardiotoxicity, suppression of TLR4 signaling and consequently inflammation pathway. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Cardioprotective effect of vanillic acid against doxorubicin-induced cardiotoxicity in rat. Res Pharm Sci. 2020 Feb 20;15(1):87-96. | |||
